Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Designing for Effective and Safe Multidisciplinary Primary Care Teamwork: Using the Time of COVID-19 as a Case Study
Lim, Lisa , Zimring, Craig , DuBose, Jennifer R. , Lee, Jaehoon , Stroebel, Robert J. , Matthews, Marc R. , Matthews, Marc R. , Lim, Lisa , Matthews, Marc R

Mayo Clinic

International Journal of Environmental Research and Public Health | August 20, 2021 | Volume: 18 | Issue: 16 | Pages: 8758

10.3390/ijerph18168758 | PMID 34444522 Get It

Effective medical teamwork can improve the effectiveness and experience of care for staff and patients, including safety. Healthcare organizations, and especially primary care clinics, have sought to improve medical teamwork through improved layout and design, moving staff into shared multidisciplinary team rooms. While co-locating staff has been shown to increase communication, successful designs balance four teamwork needs: face-to-face communications; situational awareness; heads-down work; perception of teamness. However, precautions for COVID-19 make it more difficult to conduct face-to-face communications. In this paper we describe a model for understanding how layout affects these four teamwork needs and describe how the perception of teamwork by staff changed after COVID-19 precautions were put in place. Observations, interviews and two standard surveys were conducted in two primary care clinics before COVID-19 and again in 2021 after a year of precautions. In general, staff felt more isolated and found it more difficult to conduct brief consults, though these perceptions varied by role. RNs, who spent more time on the phone, found it convenient to work part time-from home, while medical assistants found it more difficult to find providers in the distanced clinics. These cases suggest some important considerations for future clinic designs, including greater physical transparency that also allow for physical separation and more spaces for informal communication that are distanced from workstations.
Prognostic Impact of the Presence of Barrett’s Esophagus and Intestinal Metaplasia on Esophageal Adenocarcinoma Survival
Fox, Charlie, Friedman, Chloe , Marsh, Megan, McCarter, Martin D. , Kaplan, Jeffrey , Gleisner, Ana , Katzka, David A. , Wani, Sachin , Kolb, Jennifer M. , Scott, Frank I. , Han, Samuel , Lieu, Christopher H.

Mayo Clinic

Foregut: The Journal of the American Foregut Society | August 20, 2021 | Volume: 2 | Issue: 4 | Pages: 356-364

10.1177/26345161211033277 | PMID 36578279 Get It

Background/Aims: Barrett’s esophagus (BE), defined by the presence of intestinal metaplasia (IM) on histology, is thought to be the only identifiable precursor lesion for esophageal adenocarcinoma (EAC). Recent studies have suggested the possibility of an alternate, non-IM associated EAC that is a more aggressive form of EAC with worse survival. Among EAC patients, we aimed to compare survival of patients with and without IM at the time of diagnosis. Methods: This was a retrospective cohort study of all patients with histologic confirmed EAC evaluated at a tertiary care center from 2013 to 2019. Cases were categorized according to the presence or absence of IM on histologic specimens (Group I—IM-EAC and Group II—non-IM-EAC). We compared demographic characteristics, clinical stage, therapy, and survival between the 2 groups using the Chi-square and ANOVA tests (for categorical and continuous variables, respectively). We used Cox proportional hazards regression to determine the association of IM with overall survival, adjusting for sex, age at diagnosis, tumor location, histologic grade, and clinical stage. Results: A total of 475 patients were included in this analysis (mean age 64.8 years [SD 10.8], 89% white) and 109 (23.0%) had no evidence of IM. Compared with IM-EAC (Group I), individuals in the non-IM-EAC group were younger ( P = .01) and had a greater proportion of patients diagnosed with advanced disease (49.5 vs 20.2% for stage 4, P < .001). These patients were less likely to undergo endoscopic therapy alone (0.92% vs 29.78%, P < .001) or surgery alone (0 vs 9.84%, P = .001). On multivariable analysis, the presence of IM-EAC was associated with improved overall survival compared to non-IM-EAC (HR 0.69, 95% CI 0.49-0.96). Additional factors associated with poor survival was increasing stage of diagnosis (HR 6.49: 95% CI 3.77-11.15 for stage 4, HR 2.19: 95% CI 1.25-3.84 for stage 3, HR 2.04: 95% CI 0.98-4.25 for stage 2 compared to stage 1) and more advanced histologic stage (HR 2.00, 95% CI 1.26-3.19) for poorly/undifferentiated compared to well differentiated). Conclusions: EAC without the presence of IM on histology was associated with worse survival compared to those with IM. Future prospective studies with detailed molecular sequencing are required to clarify if 2 separate phenotypes of EAC exist (IM-EAC and non-IM-EAC). If confirmed, this may have significant implications for screening and management strategies.
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Shah, Pankil , Rubinstein, Samuel M. , Joyner, Michael J. , Choueiri, Toni K. , Flora, Daniel , Gulati, Anthony P., Koshkin, Vadim S. , Papadopoulos, Esperanza B. , Robilotti, Elizabeth , Su, Christopher , Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Yu, Peter Paul , Mishra, Sanjay , Senefeld, Jonathon W. , Shah, Dimpy P. , Verma, Amit , Gartrell, Benjamin A. , Ohri, Nitin , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bohachek, Pamela, Mundt, Daniel , Streckfuss, Mitrianna, Tadesse, Eyob, Lammers, Philip E. , Revankar, Sanjay G. , Khan, Hina, Prete, Salvatore A. Del , Angevine, Anne H., Bär, Michael , Lo, KM Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Nakayama, John , Gupta, Shilpa , Ahluwalia, Manmeet S. , Dawsey, Scott J. , Nizam, Amanda , Lemmon, Christopher A. , Hoppenot, Claire , Bakouny, Ziad , Bouchard, Gabrielle, Busser, Fiona, Conners, Jean M, Curran, Catherine , Demetri, George D., Kelleher, Kaitlin M. , Shaw, Grace, Nuzzo, Pier Vitale , Zon, Rebecca L. , Zhang, Tian , Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Tachiki, Lisa ML, Vinayak, Shaveta , Wagner, Michael J. , Yeh, Albert C. , Goyal, Sharad , Clément, Jessica , Daher, Ahmad , Dailey, Mark E., Hsu, Emily , Menendez, Alvaro G. , Rathmann, Joerg, Serrano, Oscar K. , Jayaraj, Asha, Accordino, Melissa , Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Shafer, Danielle , Lewis, Mark A. , Rhodes, Terence D., Gill, David , Low, Clarke A., Nagle, Sarah , Hayes‐Lattin, Brandon , Nemecek, Eneida R. , Zaren, Howard A. , Smith, Stephanie J., Akhtari, Mojtaba, Lau, Eric , Reeves, Mark E. , Elms, Destry, Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Shah, Surbhi, Rosovsky, Rachel , Reynolds, Kerry L. , Bardia, Aditya , Gainor, Justin F. , Zubiri, Leyre , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Belenkaya, Rimma , Riely, Gregory J. , Faller, Bryan A. , McKay, Rana R. , Ajmera, Archana , Cabal, Angelo , Shaya, Justin , Weissmann, Lisa B., Jani, Chinmay , Chen, James L. , Jhawar, Sachin R, Lustberg, Maryam B. , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Karivedu, Vidhya , Addison, Daniel , Menon, Harry, Rovito, Marc A., Elshoury, Amro, Shah, Mansi , Mahmood, Sana , Mico, Vasil, Rivera, Andrea Verghese, Miller, Chaim , Cabebe, Elwyn C., Glover, Michael , Jha, Alokkumar , Schapira, Lidia , Shah, Sumit , Subbiah, Suki , Logan, Barbara, Lopes, Gilberto , Russell, Karen , Stith, Brittany, Smits, Melissa, Edwin, Natasha, Chism, David D. , Owenby, Susie, Doroshow, Deborah B. , Galsky, Matthew D. , Zhu, Huili , Fu, Julie , Patel, Kanishka G. , Riess, Jonathan W. , Kwon, Daniel H. , Islam, Jessica Y. , Ahmad, Syed A. , Grover, Punita , Kharofa, Jordan , Marcum, Michelle, Park, Cathleen, Geiger, Christopher L., Bishnoi, Rohit , Feldman, Lawrence , Hoskins, Kent , Gantt, Gerald, Khan, Mahir, Nguyen, Ryan H, Schwartz, Candice, Venepalli, Neeta K. , Kasi, Anup , Fecher, Leslie A. , Mavromatis, Blanche H., Bijjula, Ragneel R., Cheng, Alex , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Reid, Sonya , Slosky, David, Solórzano, Carmen C. , Vega-Luna, Karen, Enriquez, Kyle T. , Sun, Tianyi , Carducci, Theresa M., Puc, Matthew , Loon, Susan Van, Goldsmith, Karen J., Rice, Robert, Cabalona, Wilhelmina D., Pilar, Christine, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Bilen, Mehmet Asım , Ravindranathan, Deepak , LoRusso, Patricia , Masters, Tyler, Choueiri, Toni K , Bakouny, Ziad , Mishra, Sanjay , Yeh, Albert C , Xie, Zhuoer , Zubiri, Leyre , Su, Christopher , Fiala, Mark A , Joyner, Michael J , Senefeld, Jonathon W , Ahluwalia, Manmeet S , Lustberg, Maryam , Thompson, Michael A. , Henderson, Jeffrey P. , Griffiths, Elizabeth A. , Hwang, Clara , Warner, Jeremy L. , Halmos, Balázs , Goel, Sanjay , Sica, Roberto Alejandro , Thakkar, Astha , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Panagiotou, Orestis A. , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Loaiza‐Bonilla, Arturo , Bar, Michael H, Lo, K. M. Steve, Caimi, Paolo F. , Barnholtz‐Sloan, Jill S. , Pennell, Nathan A , Li, Ang , Giordano, Antonio , Nohria, Anju , Schmidt, Andrew , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Lyman, Gary H , Graber, Jerome J. , Khaki, Ali Raza , Loggers, Elizabeth T , Nakasone, Elizabeth S. , Tachiki, Lisa M, Gatson, Na Tosha , Huynh‐Le, Minh‐Phuong , Rosenstein, Lori J. , Elias, Rawad , Gadgeel, Shirish M. , Hawley, Jessica E. , Hershman, Dawn L. , Bhutani, Divaya , Schwartz, Gary K. , Reuben, Daniel Y. , McWeeney, Shannon K. , Nagaraj, Gayathri , Berg, Stephanie , Morgans, Alicia K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Boland, Genevieve M. , Hálfdánarson, Þorvarður R. , Bekaii‐Saab, Tanios , Desai, Aakash , Mesa, Ruben A. , Ramirez, Amelie G , Philip, John , Gatti-Mays, Margaret Elena , Jhawar, Sachin R, Palmer, Joshua D. , Stover, Daniel G. , Joshi, Monika , Jabbour, Salma K , Bashir, Babar , McNair, Christopher M. , Wu, Julie , Kloecker, Goetz Hans , Fazio, Alyson, Kumar, Vaibhav , Wood, William A. , Gulati, Shuchi , Wise-Draper, Trisha Michel , Bowles, Daniel W. , Markham, Merry Jennifer , Shah, Chintan , Acoba, Jared David , Rho, Young Soo, Nguyen, Ryan H, Pasquinelli, Mary M. , Vikas, Praveen , Friese, Christopher R. , Zaman, Qamar U, Davis, Elizabeth J. , Hausrath, Daniel J. , Hsu, Chih–Yuan , Li, Xuanyi , Rini, Brian I. , Shyr, Yu , Tucker, Matthew D. , Wang, Lucy Lu , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Oncology | August 19, 2021 | Volume: 7 | Issue: 8 | Pages: 1167

10.1001/jamaoncol.2021.1799 | PMID 34137799 Get It

Gut microbiome is associated with multiple sclerosis activity in children
Horton, Mary , McCauley, Kathryn , Fadrosh, Douglas, Fujimura, Kei E. , Ness, Jayne , Wheeler, Yolanda , Gorman, Mark , Rodriguez, Moses , Tillema, Jan‐Mendelt , Belman, Anita , Mar, Soe , Casper, T. Charles , Rose, John , Hart, Janace, Shao, Xiaorong, Barcellos, Lisa F. , Horton, Mary K , Chitnis, Tanuja , Tremlett, Helen , Waubant, Emmanuelle L. , Rodriguez, Moses , Graves, Jennifer , Benson, Leslie , Weinstock‐Guttman, Bianca , Waldman, Amy , Krupp, Lauren , Rensel, Mary R. , Lynch, Susan V.

Mayo Clinic

Annals of Clinical and Translational Neurology | August 19, 2021 | Volume: 8 | Issue: 9 | Pages: 1867-1883

10.1002/acn3.51441 | PMID 34409759 Get It

Abstract Objective To identify features of the gut microbiome associated with multiple sclerosis activity over time. Methods We used 16S ribosomal RNA sequencing from stool of 55 recently diagnosed pediatric‐onset multiple sclerosis patients. Microbiome features included the abundance of individual microbes and networks identified from weighted genetic correlation network analyses. Prentice‐Williams‐Peterson Cox proportional hazards models estimated the associations between features and three disease activity outcomes: clinical relapses and both new/enlarging T2 lesions and new gadolinium‐enhancing lesions on brain MRI. Analyses were adjusted for age, sex, and disease‐modifying therapies. Results Participants were followed, on average, 2.1 years. Five microbes were nominally associated with all three disease activity outcomes after multiple testing correction. These included butyrate producers Odoribacter (relapse hazard ratio = 0.46, 95% confidence interval: 0.24, 0.88) and Butyricicoccus (relapse hazard ratio = 0.49, 95% confidence interval: 0.28, 0.88). Two networks of co‐occurring gut microbes were significantly associated with a higher hazard of both MRI outcomes (gadolinium‐enhancing lesion hazard ratios (95% confidence intervals) for Modules 32 and 33 were 1.29 (1.08, 1.54) and 1.42 (1.18, 1.71), respectively; T2 lesion hazard ratios (95% confidence intervals) for Modules 32 and 33 were 1.34 (1.15, 1.56) and 1.41 (1.21, 1.64), respectively). Metagenomic predictions of these networks demonstrated enrichment for amino acid biosynthesis pathways. Interpretation Both individual and networks of gut microbes were associated with longitudinal multiple sclerosis activity. Known functions and metagenomic predictions of these microbes suggest the important role of butyrate and amino acid biosynthesis pathways. This provides strong support for future development of personalized microbiome interventions to modify multiple sclerosis disease activity.
Skin concerns in patients with trisomy 21 (Down syndrome): A Mayo Clinic 22‐year retrospective review
Wentworth, Ashley B., Hand, Jennifer L. , Davis, Dawn Marie R. , Tollefson, Megha M. , Davis, Dawn M R

Mayo Clinic

Pediatric Dermatology | August 19, 2021 | Volume: 38 | Issue: S2 | Pages: 73-78

10.1111/pde.14764 | PMID 34409638 Get It

AbstractBackground/ObjectivesTrisomy 21 has known associated clinical phenotypes, including skin and soft tissue concerns. However, the overall prevalence and types of findings are largely unclear.MethodsA retrospective review of children with trisomy 21 and one or more dermatologic diagnoses, seen from 1/1/1994 to 7/1/2016, was performed to record dermatologic diagnoses. If one or more diagnoses were confirmed, further data were collected, including demographics, medical specialty, referrals to dermatology, treatment, complications, and follow‐up.ResultsOne hundred and seventy‐four patients with a diagnosis of trisomy 21 aged 18 years or younger were confirmed to have one or more dermatologic diagnoses. In a total of 479 dermatologic diagnoses, superficial mycoses (12%), skin and soft tissue infections (10%), dermatitis (8%), and folliculitis (8%) were most common. Diagnoses were most commonly made as an outpatient (91%) and by general pediatrics (45%) or dermatology (25%). A significant difference (P < .05) in the frequency of various diagnoses made by different specialties was observed. A significant difference (P < .05) in the treatments recommended by different specialties was also observed. Referrals to dermatology were infrequent (6%). However, a frequent change in diagnosis (61%) or treatment (68%) for patients referred to dermatology was observed.ConclusionsChildren with trisomy 21 are most commonly diagnosed with superficial mycoses, skin and soft tissue infections, dermatitis, and folliculitis. The majority of diagnoses were made by general pediatricians and although dermatology referral was rarely necessary, consultations often resulted in change of diagnosis and/or treatment, supporting consideration of early and frequent dermatology referral.
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers
Arora, Mansi , Abdelrahman, Amro M. , Alva‐Ruiz, Roberto, Leiting, Jennifer L. , Chen, Xianfeng , Usón, Pedro Luiz Serrano , Dumbauld, Chelsae, Baker, Alexander T. , Gamb, Scott I., Egan, Jan B. , Zhou, Yumei , Nagalo, Bolni Marius , Meurice, Nathalie , Eskelinen, Eeva‐Liisa , Braggio, Esteban , Barrett, Michael T. , Buetow, Kenneth H. , Roberts, Lewis R. , Bekaii‐Saab, Tanios , Ahn, Daniel H. , Truty, Mark J. , Bogenberger, James M. , Yonkus, Jennifer, Alva-Ruiz, Roberto, Leiting, Jennifer L , Serrano Uson Junior, Pedro Luiz, Dumbauld, Chelsae R, Salomao, Marcela A, Roberts, Lewis R , Braggio, Esteban , Uson, Pedro L S , Bekaii-Saab, Tanios S , Nagalo, Bolni , Baker, Alexander , Abdelrahman, Amro M , Yonkus, Jennifer A. , Salomao, Marcela , Kosiorek, Heidi , Sonbol, Mohamad Bassam , Mansfield, Aaron S. , Borad, Mitesh J.

Mayo Clinic

Hepatology | August 18, 2021 | Volume: 75 | Issue: 1 | Pages: 43-58

10.1002/hep.32102 | PMID 34407567 Get It

Abstract Background and aims Biliary tract cancers (BTCs) are uncommon, but highly lethal, gastrointestinal malignancies. Gemcitabine/cisplatin is a standard‐of‐care systemic therapy, but has a modest impact on survival and harbors toxicities, including myelosuppression, nephropathy, neuropathy, and ototoxicity. Whereas BTCs are characterized by aberrations activating the cyclinD1/cyclin‐dependent kinase (CDK)4/6/CDK inhibitor 2a/retinoblastoma pathway, clinical use of CDK4/6 inhibitors as monotherapy is limited by lack of validated biomarkers, diffident preclinical efficacy, and development of acquired drug resistance. Emerging studies have explored therapeutic strategies to enhance the antitumor efficacy of CDK4/6 inhibitors by the combination with chemotherapy regimens, but their mechanism of action remains elusive. Approach and results Here, we report in vitro and in vivo synergy in BTC models, showing enhanced efficacy, reduced toxicity, and better survival with a combination comprising gemcitabine/cisplatin and CDK4/6 inhibitors. Furthermore, we demonstrated that abemaciclib monotherapy had only modest efficacy attributable to autophagy‐induced resistance. Notably, triplet therapy was able to potentiate efficacy through elimination of the autophagic flux. Correspondingly, abemaciclib potentiated ribonucleotide reductase catalytic subunit M1 reduction, resulting in sensitization to gemcitabine. Conclusions As such, these data provide robust preclinical mechanistic evidence of synergy between gemcitabine/cisplatin and CDK4/6 inhibitors and delineate a path forward for translation of these findings to preliminary clinical studies in advanced BTC patients.
Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET
Townley, Ryan , Botha, Hugo , Graff‐Radford, Jonathan , Whitwell, Jennifer , Boeve, Bradley F. , Fields, Julie A. , Drubach, Daniel A., Savica, Rodolfo , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Josephs, Keith A. , Townley, Ryan A , Jack, Clifford R , Josephs, Keith A , Boeve, Brad , Botha, Hugo , Machulda, Mary M. , Senjem, Matthew L. , Knopman, David S. , Jones, David T.

Mayo Clinic

Brain Communications | August 17, 2021 | Volume: 3 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcab182 | PMID 34805993 Get It

Abstract Posterior cortical atrophy is a neurodegenerative syndrome with a heterogeneous clinical presentation due to variable involvement of the left, right, dorsal and ventral parts of the visual system, as well as inconsistent involvement of other cognitive domains and systems. 18F-fluorodeoxyglucose (FDG)-PET is a sensitive marker for regional brain damage or dysfunction, capable of capturing the pattern of neurodegeneration at the single-participant level. We aimed to leverage these inter-individual differences on FDG-PET imaging to better understand the associations of heterogeneity of posterior cortical atrophy. We identified 91 posterior cortical atrophy participants with FDG-PET data and abstracted demographic, neurologic, neuropsychological and Alzheimer’s disease biomarker data. The mean age at reported symptom onset was 59.3 (range: 45–72 years old), with an average disease duration of 4.2 years prior to FDG-PET scan, and a mean education of 15.0 years. Females were more common than males at 1.6:1. After standard preprocessing steps, the FDG-PET scans for the cohort were entered into an unsupervised machine learning algorithm which first creates a high-dimensional space of inter-individual covariance before performing an eigen-decomposition to arrive at a low-dimensional representation. Participant values (‘eigenbrains’ or latent vectors which represent principle axes of inter-individual variation) were then compared to the clinical and biomarker data. Eight eigenbrains explained over 50% of the inter-individual differences in FDG-PET uptake with left (eigenbrain 1) and right (eigenbrain 2) hemispheric lateralization representing 24% of the variance. Furthermore, eigenbrain-loads mapped onto clinical and neuropsychological data (i.e. aphasia, apraxia and global cognition were associated with the left hemispheric eigenbrain 1 and environmental agnosia and apperceptive prosopagnosia were associated with the right hemispheric eigenbrain 2), suggesting that they captured important axes of normal and abnormal brain function. We used NeuroSynth to characterize the eigenbrains through topic-based decoding, which supported the idea that the eigenbrains map onto a diverse set of cognitive functions. These eigenbrains captured important biological and pathophysiologic data (i.e. limbic predominant eigenbrain 4 patterns being associated with older age of onset compared to frontoparietal eigenbrain 7 patterns being associated with younger age of onset), suggesting that approaches that focus on inter-individual differences may be important to better understand the variability observed within a neurodegenerative syndrome like posterior cortical atrophy.
Adverse right ventricular remodelling, function, and stress responses in obesity: insights from cardiovascular magnetic resonance
Lewis, Andrew , Abdesselam, Inès, Rayner, Jennifer J. , Lewis, Andrew J M , Byrne, James Patrick , Borlaug, Barry A. , Neubauer, Stefan , Rider, Oliver J.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | August 17, 2021 | Volume: 23 | Issue: 10 | Pages: 1383-1390

10.1093/ehjci/jeab175 | PMID 34453521 Get It

Abstract Aims We aimed to determine the effect of increasing body weight upon right ventricular (RV) volumes, energetics, systolic function, and stress responses using cardiovascular magnetic resonance (CMR). Methods and results We first determined the effects of World Health Organization class III obesity [body mass index (BMI) &gt; 40 kg/m2, n = 54] vs. healthy weight (BMI &lt; 25 kg/m2, n = 49) upon RV volumes, energetics and systolic function using CMR. In less severe obesity (BMI 35 ± 5 kg/m2, n = 18) and healthy weight controls (BMI 21 ± 1 kg/m2, n = 9), we next performed CMR before and during dobutamine to evaluate RV stress response. A subgroup undergoing bariatric surgery (n = 37) were rescanned at median 1 year to determine the effects of weight loss. When compared with healthy weight, class III obesity was associated with adverse RV remodelling (17% RV end-diastolic volume increase, P &lt; 0.0001), impaired cardiac energetics (19% phosphocreatine to adenosine triphosphate ratio reduction, P &lt; 0.001), and reduction in RV ejection fraction (by 3%, P = 0.01), which was related to impaired energetics (R = 0.3, P = 0.04). Participants with less severe obesity had impaired RV diastolic filling at rest and blunted RV systolic and diastolic responses to dobutamine compared with healthy weight. Surgical weight loss (34 ± 15 kg weight loss) was associated with improvement in RV end-diastolic volume (by 8%, P = 0.006) and systolic function (by 2%, P = 0.03). Conclusion Increasing body weight is associated with significant alterations in RV volumes, energetic, systolic function, and stress responses. Adverse RV modelling is mitigated with weight loss. Randomized trials are needed to determine whether intentional weight loss improves symptoms and outcomes in patients with obesity and heart failure.
Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank
Naidu, Srihari S. , Baron, Suzanne J. , Eng, Marvin H. , Sathanandam, Shyam , Zidar, David A., Feldman, Dmitriy N. , Ing, Frank F. , Latif, Faisal , Lim, Michael J. , Henry, Timothy D. , Dangas, George , Hermiller, James, Daggubati, Ramesh , Ang, Lawrence , Box, Lyndon C., Caputo, Ronald , Cohen, Mauricio G. , Coylewright, Megan , Duffy, Peter L. , Goldsweig, Andrew M. , Hagler, Donald J. , Hawkins, Beau M., Hijazi, Ziyad M. , Jayasuriya, Sasanka, Klein, Andrew , Kliger, Chad , Mahmud, Ehtisham , Messenger, John C. , Parikh, Sahil A. , Shishehbor, Mehdi H. , Yakubov, Steven J. , Alvarez‐Breckenridge, Jennifer, Baird, Colleen, Baker, David, Berry, Charles H., Bhattacharya, Manisha, Bilazarian, Seth, Bowen, Rosanne, Brounstein, Kevin, Cameron, Cole, Culbertson, Casey , Díaz, P, Emanuele, Susan, Evans, Erin, Fletcher, Rob, Fortune, Tina, Gaiha, Priya, Govender, Devi, Gutfinger, Dan , Haggstrom, Kurt, Herzog, Andrea, Hite, Denise, Kalich, Bethany , Kirkland, Ann, Kohler, Toni, Laurisden, Holly, Livolsi, Kevin, Lombardi, Lois, Marhenke, Kevin, Meikle, Joie, Moat, Neil, Popma, J.J., Rangwala, Novena , Simonton, Chuck, Stokes, J. W., Taber, Margaret , Tieché, Christopher, Venditto, John, Zinn, Laurie, Dangas, George , Daggubati, Ramesh , Shah, Binita , Ang, Lawrence , Cohen, Mauricio G , Goldsweig, Andrew M , Hagler, Donald J , Morray, Brian H , Parikh, Sahil A , Shishehbor, Mehdi H , Szerlip, Molly , Yakubov, Steven J , Grines, Cindy L , Baron, Suzanne J , Rao, Sunil V. , Shah, Binita , Aronow, Herbert D. , Banerjee, Subhash , Justino, Henri , Li, Jun , Morray, Brian H. , Parikh, Sahil A. , Reilly, John P. , Secemsky, Eric A. , Grines, Cindy L. , Baker, David, Berry, Charles, Cavalcante, Rafael , Diaz, Pedro, Kohler, Toni, Lowe, Sarah, Mueller, Megan, Patarca, Roberto , Stokes, Jerry, West, Nick E.J.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 16, 2021 | Volume: 98 | Issue: 5 | Pages: 904-913

10.1002/ccd.29898 | PMID 34398509 Get It

AbstractThe Society for Cardiovascular Angiography and Interventions (SCAI) Think Tank is a collaborative venture that brings together interventional cardiologists, administrative partners, and select members of the cardiovascular industry community annually for high‐level field‐wide discussions. The 2021 Think Tank was organized into four parallel sessions reflective of the field of interventional cardiology: (a) coronary intervention, (b) endovascular medicine, (c) structural heart disease, and (d) congenital heart disease. Each session was moderated by a senior content expert and co‐moderated by a member of SCAI's Emerging Leader Mentorship program. This document presents the proceedings to the wider cardiovascular community in order to enhance participation in this discussion, create additional dialog from a broader base, and thereby aid SCAI, the industry community and external stakeholders in developing specific action items to move these areas forward.
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes
Martin, Emma C. St. , Mangaonkar, Abhishek A. , Khan, Shakila P. , Kohorst, Mira A. , Joshi, Avni Y. , Olteanu, Horatiu , Moyer, Ann M. , Al‐Kali, Aref , Tefferi, Ayalew , Chen, Dong , Wudhikarn, Kitsada , Viswanatha, David S., He, Rong , Nguyen, Phuong L., Oliveira, Jennifer L. , Gangat, Naseema , Patnaik, Mrinal M. , Herrick, Jennifer L. , St Martin, Emma C , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Chen, Dong , Viswanatha, David, He, Rong , Patnaik, Mrinal , Ferrer, Alejandro , Hogan, William J. , Go, Ronald S. , Ketterling, Rhett P. , Lasho, Terra L.

Mayo Clinic

American Journal of Hematology | August 14, 2021 | Volume: 96 | Issue: 11 | Pages: 1450-1460

10.1002/ajh.26321 | PMID 34390506 Get It

AbstractGermline predisposition syndromes (GPS) result from constitutional aberrations in tumor suppressive and homeostatic genes, increasing risk for neoplasia in affected kindred. In this study, we present clinical and genomic data on 144 Mayo Clinic patients with GPS; 59 evaluated prospectively using an algorithm‐based diagnostic approach in the setting of a dedicated GPS/ inherited bone marrow failure syndrome (IBMFS) clinic. Seventy‐two (50%) patients had IBMFS (telomere biology disorders‐32,Fanconi anemia‐18, Diamond Blackfan Anemia – 11, congenital neutropenia–5, Schwachman‐Diamond Syndrome‐5 and Bloom Syndrome‐1), 27 (19%) had GPS with antecedent thrombocytopenia (RUNX1‐FPD‐15, ANKRD26‐6, ETV6‐2, GATA1‐1, MPL‐3), 28 (19%) had GPS without antecedent thrombocytopenia (GATA2 haploinsufficiency‐16, DDX41‐10, CBL‐1 and CEBPA‐1) and 17 (12%) had general cancer predisposition syndromes (ataxia telangiectasia‐7, heterozygous ATM variants‐3, CHEK2‐2, TP53‐2, CDK2NA‐1, NF1‐1 and Nijmegen Breakage Syndrome‐1). Homozygous and heterozygous ATM pathogenic variants were exclusively associated with lymphoproliferative disorders (LPD), while DDX41 GPS was associated with LPD and myeloid neoplasms. The use of somatic NGS‐testing identified clonal evolution in GPS patients, with ASXL1, RAS pathway genes, SRSF2 and TET2 being most frequently mutated. Fifty‐two (91%) of 59 prospectively identified GPS patients had a change in their management approach, including additional GPS‐related screening in 42 (71%), referral for allogenic HSCT workup and screening of related donors in 16 (27%), medication initiation and selection of specific conditioning regimens in 14 (24%), and genetic counseling with specific intent of fertility preservation and preconceptual counseling in 10 (17%) patients; highlighting the importance of dedicated GPS screening, detection and management programs for patients with hematological neoplasms.